© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts discusses current strategies used to stratify risk in patients with myelofibrosis and their preferences for sequencing therapy.
November 11th 2021
The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.
November 15th 2021
Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
November 24th 2021
Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.
Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.
December 2nd 2021
Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis.
Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.
December 6th 2021
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.